Aspire Biopharma Holdings, Inc. (ASBP)
8.92
+0.31
(+3.60%)
USD |
NASDAQ |
Sep 10, 13:28
Aspire Biopharma Holdings Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.3875 |
| December 31, 2025 | -0.8116 |
| September 30, 2025 | -0.7521 |
| June 30, 2025 | -0.8811 |
| March 31, 2025 | -0.9729 |
| December 31, 2024 | -0.8225 |
| September 30, 2024 | 59.14 |
| June 30, 2024 | 8.540 |
| March 31, 2024 | 0.1138 |
| Date | Value |
|---|---|
| December 31, 2023 | 0.0006 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | -477.20 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Resonate Blends, Inc. | -1.103 |
| Breakthrough Chemistry, Inc. | 0.2335 |
| Kaya Holdings, Inc. | -- |
| Cardiac Biotech Solutions, Inc. | -0.2375 |
| Endexx Corp. | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 13.54M |
| Total Liabilities (Quarterly) | 1.783M |
| Shareholders Equity (Quarterly) | 11.76M |
| Current Ratio | 7.986 |
| Net Debt Paydown Yield | 19.56% |